New asthma drug under watch: tezepelumab study launches in korea
NCT ID NCT06998095
First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This study tracks 210 people with severe asthma in South Korea who are prescribed Tezepelumab (Tezspire). Researchers will watch for side effects and check if the drug helps control asthma over 24 weeks. The goal is to see how well the drug works in real-world use, not to cure asthma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.